The ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) will present data from PROSPER RCC (EA8143), the first randomized phase 3 trial of neoadjuvant immunotherapy in patients with kidney cancer. Patients with high-risk renal ...
Sep 8, 2022
0
16
A University of Cincinnati study found administering an immunotherapy drug before surgery for oral cavity cancer did not lead to increased rates of complications during and after surgery.
Sep 7, 2022
0
10
Lupus is an autoimmune disease that attacks organs and can be fatal. There's no cure, so current treatments aim to limit damage and ameliorate symptoms. Some of these therapies have to be injected, some have serious side ...
Aug 21, 2022
0
363
A score has been developed to stratify the risk for subclinical rheumatoid arthritis-associated interstitial lung disease (RA-ILD), according to a study published online May 18 in Arthritis & Rheumatology.
Jun 23, 2022
0
22
In a Phase II clinical trial, immune checkpoint blockade before surgery was associated with favorable responses and outcomes in undifferentiated pleomorphic sarcoma (UPS) and recurrent dedifferentiated liposarcoma (DDLPS), ...
Jun 6, 2022
0
11
An experimental drug restored brain synapses in two mouse models of Alzheimer's disease, raising hopes that it could help revive cognitive function in human dementia patients, Yale University researchers report June 1 in ...
Jun 2, 2022
0
211
Immunotherapy after surgery helped reduce cancer recurrence in patients with urothelial cancer of the bladder or other sites in the urinary tract that had invaded the muscle and therefore posed a high risk for recurrence, ...
May 15, 2022
0
108
Adding the immunotherapy drug nivolumab to chemotherapy before surgery (neoadjuvant) for patients with operable non-small cell lung cancer (NSCLC)—the leading cause of cancer deaths worldwide—reduced the risk of recurrence ...
Apr 11, 2022
0
3
A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath, according to late-breaking research presented today at the American College of Cardiology (ACC) Scientific Session ...
Apr 3, 2022
0
6
For patients with previously untreated metastatic or unresectable melanoma, the combination of relatlimab + nivolumab continues to demonstrate a progression-free survival (PFS) benefit over nivolumab alone, according to updated ...
Mar 21, 2022
0
13
